Article
bit.bio featured in Forbes
The piece covers the launch of bit.bio's Custom ioDisease Model Cells at the SynBioBeta conference.
06.06.2023Content type
News
Article
Meet the company reprogramming the future of synthetic biology
SynbioBeta CEO John Cumbers talks reimagining cell therapies through cell reprogramming with Rick Klausner and bit.bio CEO.
Article
Can we recreate every human cell type in the body? This UK startup thinks so
bit.bio and the London Institute of Mathematical Sciences (LIMS) want to recreate every human cell type.